Table 3.

Global studies of HIF-PHI.

	Trials	n	ESA	Comparator	Period (wks)	Ref
Roxadustat	phase 3
NDD	ALPS	594	Naïve	Placebo	52	[135]
	DOLOMITES	616	Naïve	DA	104	[136]
	ANDES	922	Naïve	Placebo	52–234	[137]
	OLYMPUS	2781	Naïve	Placebo	52–208	[138]
Incident DD	HIMALAYAS	1043	Naïve	Epoetin alfa	52	[139]
DD	ROCKIES	2133	Naïve	Epoetin alfa	52	[140]
			User
	SIERRAS	741	User	Epoetin alfa	52	[141]
	PYRENEES	836	User	DA or epoetin alfa	52–104	[142]
Vadadustat	phase 3
NDD	PRO2TECT	1751	Naïve	DA	52	[143]
		1725	User	DA	52
Incident DD	INNO2VATE	369	User	DA	52	[144]
DD		3554	User	DA	52
Daprodustat	phase 3
NDD	ASCEND-ND	3872	Naïve	DA	52	[145]
DD	ASCEND-D	2964	User	Epoetin alfa (HD)	52	[146]
				Subctaneous DA (PD)
	ASCEND-ID	312	Limited user	DA	52	[147]
	ASCEND-TD	407	User	Epoetin alfa	52	[148]
Molidustat	phase 2b
NDD	DIALOGUE 1	121	Naïve	Placebo	16	[149]
	DIALOGUE 2	124	User	DA	16
HD	DIALOGUE 4	199	User	Epoetin alfa/beta	16
	Extension Studies					[150]
NDD	DIALOGUE 3	83	Naïve	Placebo	36
		77	User	DA	36
HD	DIALOGUE 5	87	User	Epoetin alfa/beta	36

DA, darbepoetin alfa; DD, dialysis dependent; ESA, erythropoiesis-stimulating agent; HD, hemodialysis; NDD, non-dialysis dependent; PD, peritoneal dialysis.